| Literature DB >> 30834239 |
Fokhrul Hossain1, Denise Danos1, Om Prakash1, Aubrey Gilliland2, Tekeda F Ferguson2, Neal Simonsen3, Claudia Leonardi2, Qingzhao Yu2, Xiao-Cheng Wu2, Lucio Miele1, Richard Scribner2.
Abstract
Triple Negative Breast Cancer (TNBC) is an aggressive, heterogeneous subtype of breast cancer, which is more frequently diagnosed in African American (AA) women than in European American (EA) women. The purpose of this study is to investigate the role of social determinants in racial disparities in TNBC. Data on Louisiana TNBC patients diagnosed in 2010-2012 were collected and geocoded to census tract of residence at diagnosis by the Louisiana Tumor Registry. Using multilevel statistical models, we analyzed the role of neighborhood concentrated disadvantage index (CDI), a robust measure of physical and social environment, in racial disparities in TNBC incidence, stage at diagnosis, and stage-specific survival for the study population. Controlling for age, we found that AA women had a 2.21 times the incidence of TNBC incidence compared to EA women. Interestingly, the incidence of TNBC was independent of neighborhood CDI and adjusting for neighborhood environment did not impact the observed racial disparity. AA women were more likely to be diagnosed at later stages and CDI was associated with more advanced stages of TNBC at diagnosis. CDI was also significantly associated with poorer stage-specific survival. Overall, our results suggest that neighborhood disadvantage contributes to racial disparities in stage at diagnosis and survival among TNBC patients, but not to disparities in incidence of the disease. Further research is needed to determine the mechanisms through which social determinants affect the promotion and progression of this disease and guide efforts to improve overall survival.Entities:
Keywords: SEER database; concentrated disadvantage; multi-level modeling; racial disparity; socioeconomic factors; triple negative breast cancer
Year: 2019 PMID: 30834239 PMCID: PMC6387917 DOI: 10.3389/fpubh.2019.00018
Source DB: PubMed Journal: Front Public Health ISSN: 2296-2565
Demographics and tumor stage characteristics of breast cancer patients by molecular subtype, Louisiana 2010–2012.
| N | 5,650 | 944 | 410 | 1,216 |
| 30–39 | 2.81 | 5.51 | 8.05 | 7.32 |
| 40–49 | 13.27 | 17.16 | 17.80 | 18.59 |
| 50–59 | 23.86 | 24.79 | 27.07 | 29.28 |
| 60–69 | 27.65 | 25.53 | 26.34 | 23.52 |
| 70+ | 32.41 | 27.01 | 20.73 | 21.30 |
| White | 73.82 | 69.70 | 61.46 | 51.81 |
| Black | 25.33 | 29.77 | 37.56 | 47.45 |
| Other | 0.85 | 0.53 | 0.98 | 0.74 |
| Local | 64.12 | 56.04 | 51.95 | 57.81 |
| Regional | 30.48 | 36.12 | 37.32 | 33.31 |
| Distant | 5.12 | 7.73 | 10.49 | 8.39 |
| Unknown | 0.28 | 0.11 | 0.24 | 0.49 |
| Mean (Std Dev) | −0.21 (0.88) | −0.16 (0.9) | −0.04 (0.91) | 0.00 (0.97) |
(N = 8,220). HR, Hormone Receptor; HER2, Human Epidermal Growth Factor 2; TNBC, Triple Negative Breast Cancer; SEER, Surveillance, Epidemiology and End Results Program; CDI, Concentrated Disadvantage Index.
https://www.registrypartners.com/seer-summary-staging-manual-2000/
Figure 1Age-specific unadjusted incidence of triple-negative breast cancer among females by race, Louisiana 2010–2012.
Figure 2Distribution of concentrated disadvantage index among female triple negative breast cancer patients by race, Louisiana 2010–2012. CDI is a sample-based index, where scores have a mean of 0 and a standard deviation of 1. Therefore, a single unit increase in CDI represents a one standard deviation increase in neighborhood disadvantage.
Estimated risk ratios (RR) and 95% confidence intervals (CI) from multilevel binomial regression of triple negative breast cancer, Louisiana 2010–2012.
| 30–39 (reference) | 1.00 | 1.00 |
| 40–49 | 2.33 (1.82, 2.99) | 2.33 (1.82, 2.99) |
| 50–59 | 3.68 (2.91, 4.66) | 3.69 (2.92, 4.66) |
| 60–69 | 4.44 (3.49, 5.65) | 4.45 (3.50, 5.66) |
| 70+ | 4.06 (3.18, 5.18) | 4.07 (3.19, 5.20) |
| White (reference) | 1.00 | 1.00 |
| Black | 2.21 (1.96, 2.48) | 2.30 (2.01, 2.64) |
| 1 SD Increase | – | 0.96 (0.89, 1.03) |
RR, risk ratio; CI, confidence interval; CDI, concentrated disadvantage index; SD, standard deviation.
Model 1 is adjusted for age and race. Model 2 is adjusted for age, race and CDI.
All models include random intercept for US census tracts.
Estimated odds ratios (OR) and 95% confidence intervals (CI) from multilevel proportional odds logistic regression models of SEER stage at diagnosis in triple negative breast cancer, Louisiana 2010–2012.
| 30–39 (reference) | 1.00 | 1.00 |
| 40–49 | 0.62 (0.38, 1.02) | 0.62 (0.38, 1.01) |
| 50–59 | 0.56 (0.35, 0.90) | 0.56 (0.35, 0.89) |
| 60–69 | 0.74 (0.46, 1.19) | 0.72 (0.45, 1.15) |
| 70+ | 0.66 (0.40, 1.07) | 0.64 (0.39, 1.04) |
| White (reference) | 1.00 | 1.00 |
| Black | 1.42 (1.11, 1.81) | 1.17 (0.88, 1.56) |
| 1 SD Increase | 1.20 (1.03, 1.39) | |
OR, odds ratio; CI, confidence interval; SEER, Surveillance, Epidemiology and End Results Program; CDI, concentrated disadvantage index; SD, standard deviation.
Model 1 is adjusted for age and race. Model 2 is adjusted for age, race and CDI.
All models include random intercept for US census tracts.
Figure 3Kaplan-Meier SEER stage-specific survival plots of triple negative breast cancer patients by race, Louisiana 2010–2012.
Estimated hazard ratios (HR) and 95% confidence intervals (CI) from Cox proportional hazards model of cancer-related death in triple negative breast cancer, Louisiana 2010–2012.
| Local (reference) | 1.00 | 1.00 |
| Regional | 4.03 (2.76, 5.91) | 4.01 (2.75, 5.86) |
| Distant | 26.30 (17.4, 39.76) | 24.70 (16.47, 37.04) |
| 30–39 (reference) | 1.00 | 1.00 |
| 40–49 | 0.59 (0.33, 1.07) | 0.58 (0.32, 1.04) |
| 50–59 | 0.78 (0.46, 1.33) | 0.77 (0.46, 1.30) |
| 60–69 | 1.01 (0.59, 1.72) | 0.99 (0.59, 1.68) |
| 70+ | 1.25 (0.72, 2.16) | 1.16 (0.67, 1.99) |
| White (reference) | 1.00 | 1.00 |
| Black | 1.08 (0.80, 1.46) | 0.88 (0.62, 1.25) |
| 1 SD Increase | – | 1.19 (1.01, 1.39) |
The event of interest is breast cancer-related death among triple negative breast cancer patients in Louisiana, diagnosed 2010–2012. HR, hazard ratio; CI, confidence interval; SEER, Surveillance, Epidemiology and End Results Program; CDI, concentrated disadvantage index; SD, standard deviation.
Model 1 is adjusted for SEER stage, age and race. Model 2 is adjusted for SEER stage, age, race and CDI.
Models include random intercept (frailty term) for US census tracts.
https://www.registrypartners.com/seer-summary-staging-manual-2000/